BioLineRx (BLRX) Enrolls First Patients in BL-8020 Phase I/II as HCV Treatment
Tweet Send to a Friend
BioLineRx (Nasdaq: BLRX) announced enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
